




# Algoritam za rano otkrivanje i praćenje liječenja hronične bubrežne bolesti kod bolesnika sa dijabetesom tipa 2 (T2D)<sup>1-12</sup>



\*UACR ne određivati kod: infekcija ili upalnih procesa, povišene tjelesne temperature, intenzivne fizičke aktivnosti (24h prije uzimanja uzorka).  
Pri tumačenju nalaza u obzir uzeti: pušenje, nekontrolisanu hipertenziju, kongestivno zatajenje srca i ostala stanja (npr. Ortostatska proteinurija).  
\*\*Ako je UACR ≥ 70mg/mmol, ponovno uzimanje uzorka nije potrebno  
UACR - Urine Albumin-to-Creatinine Ratio

**Nizak rizik**  
Stabilna bolest ili bez HBB u nedostatku drugih markera oštećenja bubrega. Zahtijeva mjerenja jedanput (1) na godinu

**Umjereno povećan rizik**  
Zahtijeva mjerenja najmanje jedanput (1) na godinu

**Visok rizik**  
Zahtijeva mjerenja najmanje dvaput (2) na godinu

**Vrlo visok rizik**  
Liječenje uz savjetovanje s nefrologom  
Zahtijeva pažljivo praćenje / mjerenja najmanje tri do četiri (3-4) puta na godinu

Konsenzus radne skupine održane 30.5.2024. u sklopu projekta "Algoritam za rano otkrivanje i praćenje liječenja hronične bubrežne bolesti kod pacijenata sa dijabetesom tip 2". "Razvijeno u saradnji s članovima radne grupe: Topić G., Bubić D., Kovačević Preradović T., Kuprešak D., Savić S., Lovrić M., Risović I.  
HBB = hronična bubrežna bolest; T2D = dijabetes tipa 2; eGFR = procijenjena glomerulna filtracija; UACR = omjer albumin/kreatinin u urinu; ACEi = inhibitor konvertaze angiotenzina I; ARB = blokator AT2 receptora za angiotenzin II; GLP1-RA = agonist receptora peptida-1 sličnoga glukagonu; SGLT2i = inhibitor suprijenosnika za natrij i glukozu tipa 2; nsMRA = nesteroidni antagonist mineralokortikoidnih receptora

Reference: 1. Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. *Endocr Pract.* 2022 Oct;28(10):923-1049. 2. de Boer IH, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care.* 2022 Dec 1;45(12):3075-3090. 3. Cosentino F, et al; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J.* 2020 Jan 7;41(2):255-323. 4. ElSayed NA, et al. on behalf of the American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care.* 2023 Jan 1;46(Suppl 1):S158-S190. 5. ElSayed NA, et al. On behalf of the American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care* 1 January 2023; 46 (Supplement\_1): S191-S202. 6. Rossing P, et al. on behalf of Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline or Diabetes Management in Chronic Kidney Disease. *Kidney Int.* 2022 Nov;102(5S):S1-S127. 7. Mancia G,

et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens.* 2023 Dec 1;41(12):1874-2071. 8. Marx N, et al. on behalf of ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J.* 2023 Oct 14;44(39):4043-4140. 9. McDonagh TA, et al. on behalf of ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2023 Oct 1;44(37):3627-3639. 10. McGill JB, et al. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. *BMJ Open Diab Res Care* 2022;10:e002806. 11. NICE guidance - diabetic renal disease in type II diabetes. Last reviewed 25 Oct 2023, available at <https://gnotebook.com/pages/diabetes-and-endocrinology/nice-guidance-diabetic-renal-disease-in-type-ii-diabetes>. Zadnji pristup 12. 12. 2023. 12. NICE Guideline. Chronic kidney disease: assessment and management, available at <https://www.nice.org.uk/guidance/ng203>, Zadnji pristup 12.12.2023

STRUČNI POKROVITELJI:



Sponzorirano od Bayer d.o.o. Sarajevo  
Samo za zdravstvene radnike.  
Bayer d.o.o., Trg solidarnosti 2A, 71000 Sarajevo